PVG.L Regulatory News (PVG)

5 Dec 2007 12:41

Ark Therapeutics Group PLC05 December 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES (1). Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached: ARK THERAPEUTICS GROUP PLC 2. Reason for the notification (please state Yes/No): ( ) An acquisition or disposal of voting rights: ( X ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( X ) Other : Transitional disclosure required following the implementationof the DTR rules ( ) 3. Full name of person(s) subject to the notification obligation: Hansa Capital Partners LLP 4. Full name of shareholder(s) (if different from 3.): Deutsche is Deutsche Bank Nominees (Jersey) Limited - A/C HAML OWILBank of New York Mellon (OCS) Nominees Limited - A/C 339552 HANT 5. Date of the transaction and date on which the threshold is crossed or reachedif different): 30 November 2007 6. Date on which issuer notified: 4 December 2007 7. Threshold(s) that is/are crossed or reached: Under 3% 8. Notified details: A: Voting rights attached to shares Class/type of shares Situation previous to if possible using the the Triggering ISIN CODE transaction Number of shares Number of voting Rights Ordinary 5,375,000 3.24%GB0034251727 Resulting situation after the triggering transaction Class/type of shares Number of shares Number of voting rights % of voting rights if possible using the ISIN CODE Direct Direct Indirect Direct Indirect OrdinaryGB0034251727 6,057,909 5,776,146 281,763 2.86% 0.13% B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Date Exercise/Conversion Number of voting % of voting financial Period/ Date rights that may be rights instrument acquired if the instrument is exercised/ converted. N/A Total (A+B)Number of voting rights % of voting rights 6,057,909 2.99% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: N/A 14. Contact name: James Siddalls 15. Contact telephone number: 020 7647 5750 16. Contact name and telephone at issuer: NICK PLUMMERCompany SecretaryArk Therapeutics Group plc 020 7388 7722 5 December 2007 This information is provided by RNS The company news service from the London Stock Exchange